Nicole Kucine1. 1. Department of Pediatrics, Division of Hematology/Oncology, Weill Cornell Medicine, 525 E. 68th St., Payson-695, New York, NY, 10065, USA. nik9015@med.cornell.edu.
Abstract
PURPOSE OF REVIEW: Myeloproliferative neoplasms are traditionally seen in older adults, making them poorly understood in younger patients. Clinical presentation, genetic landscape, outcomes, and best management practices are inadequately described in this group. Over the past decade, more research has focused on younger patients, and this paper seeks to review and describe the current status of the field. RECENT FINDINGS: A recent review analyzed the available pediatric MPN literature and highlighted the paucity of published data. Pediatric patients showed lower rates of the common mutations found in adults, thrombotic events, and disease transformation to myelofibrosis and acute leukemia. A number of centers have recently shared their experience with young adult patients. Better survival outcomes were confirmed for young adult patients compared to older patients. There is still much to learn about myeloproliferative neoplasms in pediatric and young adult patients, but currently available data showing better outcomes is reassuring.
PURPOSE OF REVIEW: Myeloproliferative neoplasms are traditionally seen in older adults, making them poorly understood in younger patients. Clinical presentation, genetic landscape, outcomes, and best management practices are inadequately described in this group. Over the past decade, more research has focused on younger patients, and this paper seeks to review and describe the current status of the field. RECENT FINDINGS: A recent review analyzed the available pediatric MPN literature and highlighted the paucity of published data. Pediatric patients showed lower rates of the common mutations found in adults, thrombotic events, and disease transformation to myelofibrosis and acute leukemia. A number of centers have recently shared their experience with young adult patients. Better survival outcomes were confirmed for young adult patients compared to older patients. There is still much to learn about myeloproliferative neoplasms in pediatric and young adult patients, but currently available data showing better outcomes is reassuring.
Entities:
Keywords:
Essential thrombocytosis; Pediatric; Polycythemia vera; Primary myelofibrosis; Young adult
Authors: Tiziano Barbui; Ayalew Tefferi; Alessandro M Vannucchi; Francesco Passamonti; Richard T Silver; Ronald Hoffman; Srdan Verstovsek; Ruben Mesa; Jean-Jacques Kiladjian; Rȕdiger Hehlmann; Andreas Reiter; Francisco Cervantes; Claire Harrison; Mary Frances Mc Mullin; Hans Carl Hasselbalch; Steffen Koschmieder; Monia Marchetti; Andrea Bacigalupo; Guido Finazzi; Nicolaus Kroeger; Martin Griesshammer; Gunnar Birgegard; Giovanni Barosi Journal: Leukemia Date: 2018-02-27 Impact factor: 11.528
Authors: Animesh D Pardanani; Ross L Levine; Terra Lasho; Yana Pikman; Ruben A Mesa; Martha Wadleigh; David P Steensma; Michelle A Elliott; Alexandra P Wolanskyj; William J Hogan; Rebecca F McClure; Mark R Litzow; D Gary Gilliland; Ayalew Tefferi Journal: Blood Date: 2006-07-25 Impact factor: 22.113
Authors: Fariba Navid; Cynthia E Herzog; John Sandoval; Vinay M Daryani; Clinton F Stewart; Jami Gattuso; Belinda Mandrell; Sean Phipps; Wassim Chemaitilly; April Sykes; Andrew M Davidoff; Barry L Shulkin; Armita Bahrami; Wayne L Furman; Shenghua Mao; Jianrong Wu; Deborah Schiff; Bhaskar Rao; Alberto Pappo Journal: Pediatr Blood Cancer Date: 2016-04-01 Impact factor: 3.167
Authors: Yelena Z Ginzburg; Maria Feola; Eran Zimran; Judit Varkonyi; Tomas Ganz; Ronald Hoffman Journal: Leukemia Date: 2018-07-24 Impact factor: 11.528